Poxel Cours Action Courses

Poxel SA is a specialty pharmaceutical company that develops drugs to treat type 2 diabetes and non-alcoholic steatohepatitis (NASH). The company has advanced two core programs: Imeglimin, an oral anti-diabetic agent, and PXL770, a first-in-class process for NASH patients. Imeglimin’s Phase 3 clinical program concluded with positive results in 2019, and the company is preparing for a New Drug Application (NDA) submission in 2020. PXL770 is in Phase 1 of a clinical trial using its proprietary formulation technology. Poxel’s stock trades on the Euronext stock exchange under the symbol POXEL. In recent years, the stock has seen significant appreciation as the company’s product pipeline has progressed. Investors have been optimistic about Poxel’s potential, given the potential billion-dollar markets for both its lead products. The Poxel stock price has seen substantial growth in 2020, with the shares currently trading at €11.27. This represents a 31.1% increase year-to-date. The company’s market cap stands at €711.59 million, with over 6.39 million shares outstanding. Poxel shares offer a dividend yield of 0.42%.